274 related articles for article (PubMed ID: 28013453)
1. PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease.
Xiao AJ; Caro L; Popejoy MW; Huntington JA; Kullar R
Infect Dis Ther; 2017 Mar; 6(1):137-148. PubMed ID: 28013453
[TBL] [Abstract][Full Text] [Related]
2. Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
Xiao AJ; Huntington JA; Long J; Caro L
Int J Antimicrob Agents; 2018 Sep; 52(3):324-330. PubMed ID: 29596902
[TBL] [Abstract][Full Text] [Related]
3. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
Natesan S; Pai MP; Lodise TP
J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
[TBL] [Abstract][Full Text] [Related]
4. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
Xiao AJ; Miller BW; Huntington JA; Nicolau DP
J Clin Pharmacol; 2016 Jan; 56(1):56-66. PubMed ID: 26096377
[TBL] [Abstract][Full Text] [Related]
5. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Cho JC; Fiorenza MA; Estrada SJ
Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.
Kakara M; Larson K; Feng HP; Shiomi M; Yoshitsugu H; Rizk ML
J Infect Chemother; 2019 Mar; 25(3):182-191. PubMed ID: 30528208
[TBL] [Abstract][Full Text] [Related]
7. Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections.
Giancola SE; Mahoney MV; Bias TE; Hirsch EB
Ther Clin Risk Manag; 2016; 12():787-97. PubMed ID: 27279744
[TBL] [Abstract][Full Text] [Related]
8. Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
Feng HP; Patel YT; Zhang Z; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda C; Gao W
J Clin Pharmacol; 2023 Feb; 63(2):166-171. PubMed ID: 36046982
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance.
Nicolau DP; De Waele J; Kuti JL; Caro L; Larson KB; Yu B; Gadzicki E; Zeng Z; Rhee EG; Rizk ML
Int J Antimicrob Agents; 2021 Apr; 57(4):106299. PubMed ID: 33567333
[TBL] [Abstract][Full Text] [Related]
10. Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.
Larson KB; Patel YT; Willavize S; Bradley JS; Rhee EG; Caro L; Rizk ML
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962340
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.
Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358583
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Tato M; García-Castillo M; Bofarull AM; Cantón R;
Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
[TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/Tazobactam Dosing Requirements Against
Ruiz J; Ferrada A; Salavert M; Gordon M; Villarreal E; Castellanos-Ortega Á; Ramirez P
Dose Response; 2020; 18(1):1559325819885790. PubMed ID: 32063809
[TBL] [Abstract][Full Text] [Related]
15. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
Pfaller MA; Bassetti M; Duncan LR; Castanheira M
J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
[TBL] [Abstract][Full Text] [Related]
16. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa.
Pilmis B; Petitjean G; Lesprit P; Lafaurie M; El Helali N; Le Monnier A;
Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1457-1461. PubMed ID: 31073653
[TBL] [Abstract][Full Text] [Related]
17. Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.
Shorr AF; Bruno CJ; Zhang Z; Jensen E; Gao W; Feng HP; Huntington JA; Yu B; Rhee EG; De Anda C; Basu S; Kollef MH
Crit Care; 2021 Oct; 25(1):354. PubMed ID: 34600585
[TBL] [Abstract][Full Text] [Related]
18. Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing.
Gatti M; Giannella M; Raschi E; Viale P; De Ponti F
J Antimicrob Chemother; 2021 Jan; 76(1):199-205. PubMed ID: 33057628
[TBL] [Abstract][Full Text] [Related]
19. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
Noel AR; Bowker KE; Attwood M; MacGowan AP
J Antimicrob Chemother; 2018 Sep; 73(9):2411-2417. PubMed ID: 30020472
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
